Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Parallel- group, Placebo-controlled, Confirmatory Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase3>

Trial Profile

Randomized, Double-blind, Parallel- group, Placebo-controlled, Confirmatory Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase3>

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms PASTEL
  • Sponsors Sumitomo Dainippon Pharma; Sumitomo Pharma
  • Most Recent Events

    • 30 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 24 Apr 2015 Interim results published in the Media Release.
    • 24 Apr 2015 Sumitomo Dainippon Pharma announced in a media release that based on results of a pre-specified interim analysis, the company does not believe the trial results would warrant approval of production and distribution of lurasidone for the treatment of patients with schizophrenia in Japan, and is now reviewing its lurasidone development policy for Japan.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top